Bay 73-6691, an inaugural phosphodiesterase inhibitor selective for the PDE9A subtype, has previously been employed in studies to ameliorate memory deficits and cognitive impairments in Alzheimer’s disease. Here, PDE9A is linked to Alzheimer disease.